hrcak mascot   Srce   HID

Stručni rad

Prednisolone Neuroprotective Therapy in Age-Related Macular Degeneration

Božidar Vojniković
Josip Španjol

Puni tekst: engleski, pdf (53 KB) str. 69-70 preuzimanja: 225* citiraj
APA 6th Edition
Vojniković, B. i Španjol, J. (2007). Prednisolone Neuroprotective Therapy in Age-Related Macular Degeneration. Collegium antropologicum, 31 - Supplement 1 (1), 69-70. Preuzeto s https://hrcak.srce.hr/27427
MLA 8th Edition
Vojniković, Božidar i Josip Španjol. "Prednisolone Neuroprotective Therapy in Age-Related Macular Degeneration." Collegium antropologicum, vol. 31 - Supplement 1, br. 1, 2007, str. 69-70. https://hrcak.srce.hr/27427. Citirano 24.07.2019.
Chicago 17th Edition
Vojniković, Božidar i Josip Španjol. "Prednisolone Neuroprotective Therapy in Age-Related Macular Degeneration." Collegium antropologicum 31 - Supplement 1, br. 1 (2007): 69-70. https://hrcak.srce.hr/27427
Harvard
Vojniković, B., i Španjol, J. (2007). 'Prednisolone Neuroprotective Therapy in Age-Related Macular Degeneration', Collegium antropologicum, 31 - Supplement 1(1), str. 69-70. Preuzeto s: https://hrcak.srce.hr/27427 (Datum pristupa: 24.07.2019.)
Vancouver
Vojniković B, Španjol J. Prednisolone Neuroprotective Therapy in Age-Related Macular Degeneration. Collegium antropologicum [Internet]. 2007 [pristupljeno 24.07.2019.];31 - Supplement 1(1):69-70. Dostupno na: https://hrcak.srce.hr/27427
IEEE
B. Vojniković i J. Španjol, "Prednisolone Neuroprotective Therapy in Age-Related Macular Degeneration", Collegium antropologicum, vol.31 - Supplement 1, br. 1, str. 69-70, 2007. [Online]. Dostupno na: https://hrcak.srce.hr/27427. [Citirano: 24.07.2019.]

Sažetak
134 patients with Age-related Macular Degeneration (AMD) (aging 47–75 years) were treated in therapy procedure
with parabulbar injections of Methylprednisolone Acetate and Prednisolone Acetate. In the first group of patients with
AMD (n=71 patients) were treated with Methylprednisolone acetate, and second group (n=63 patients) with Prednisolone
acetate. Each patient was given doses of 60 mg, through two weeks, l0 mg every second day. It's estimated in all patients
ameliorate in macular threshold, so that it's in the group with Methylprednisolone treatment, ameliorate effect begins
after first week, than in second group, treated with Prednisolone, initial ameliorate effect is after second week.
Complete effect in both groups is after 2 months. It can be concluded that the treatment of AMD with glucocorticoids has
the ameliorate effect in vision loss and it is decided that earlier effect in the group treated with Methylprednisolone, is
probably of higher affinity for glucocorticoid receptors.

Ključne riječi
macular degeneration; glucocorticoid therapy; neuroprotection

Hrčak ID: 27427

URI
https://hrcak.srce.hr/27427

Posjeta: 359 *